Vinay Prasad has been reinstated as director of the FDA’s Center for Biologics Evaluation and Research (CBER) just two weeks after his ouster following political controversy. The return was encouraged by FDA leadership and received mixed market reactions. Meanwhile, other industry developments include new executive appointments, regulatory uncertainties, and a presidential executive order aimed at tightening oversight of federal research grants, emphasizing expenditure scrutiny and increased competition beyond academia.